RxSight, Inc.
RXSTNASDAQHealthcare● Active
$4.95
$-0.05(-1.00%)
Market Cap$204913210
P/E Ratio—
52W High$16
52W Low$4.7
RxSight, Inc. (RXST) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RXST · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.38
Est. -$0.30 · -27.1%
Revenue
$0.03B
Est. $0.03B · +3.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
RXST reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.21 | — | — | — | $0.03B | — |
| ▼ Q2 FY2026 | May 6, 2026 | -$0.30 | -$0.38 | -27.1% | $0.03B | $0.03B | +3.8% |
| ▲ Q1 FY2026 | Feb 25, 2026 | -$0.33 | -$0.22 | +34.3% | $0.03B | $0.03B | +8.1% |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.19 | -$0.04 | +79.0% | $0.03B | $0.03B | -6.9% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.10 | -$0.08 | +20.0% | $0.03B | $0.03B | +30.6% |
| ▲ Q2 FY2025 | May 7, 2025 | -$0.22 | -$0.20 | +7.7% | $0.04B | $0.04B | -0.5% |
| ▼ Q1 FY2025 | Feb 25, 2025 | $0.10 | $0.03 | -70.0% | $0.04B | $0.04B | +1.1% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.25 | -$0.16 | +36.0% | $0.05B | $0.04B | +12.5% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.21
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
-$0.38
EPS Est.
-$0.30
EPS Surpr.
-27.1%
Revenue
$0.03B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
-$0.22
EPS Est.
-$0.33
EPS Surpr.
+34.3%
Revenue
$0.03B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.04
EPS Est.
-$0.19
EPS Surpr.
+79.0%
Revenue
$0.03B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$0.10
EPS Surpr.
+20.0%
Revenue
$0.03B
Q2 FY2025
May 7, 2025Beat
EPS Actual
-$0.20
EPS Est.
-$0.22
EPS Surpr.
+7.7%
Revenue
$0.04B
Q1 FY2025
Feb 25, 2025Miss
EPS Actual
$0.03
EPS Est.
$0.10
EPS Surpr.
-70.0%
Revenue
$0.04B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.16
EPS Est.
-$0.25
EPS Surpr.
+36.0%
Revenue
$0.05B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.27 | $-0.26 | $-0.25 | 1 |
| Q3 FY2028 | $-0.29 | $-0.28 | $-0.27 | 1 |
| Q2 FY2028 | $-0.30 | $-0.29 | $-0.28 | 1 |
| Q1 FY2028 | $-0.27 | $-0.26 | $-0.25 | 1 |
| Q4 FY2027 | $-0.34 | $-0.33 | $-0.31 | 1 |
| Q3 FY2027 | $-0.33 | $-0.32 | $-0.31 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -27.1% | $7.26 | $6.78 | -6.61% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +34.3% | $8.94 | $8.81 | -1.45% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +79.0% | $9.00 | $8.34 | -7.33% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +20.0% | $7.55 | $7.79 | +3.18% |
| ▲ Q2 FY2025 | May 7, 2025 | +7.7% | $13.95 | $14.90 | +6.81% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -70.0% | $29.29 | $29.21 | -0.27% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +36.0% | $54.73 | $50.85 | -7.09% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +27.3% | $41.77 | $40.78 | -2.37% |
Q2 FY2026-6.61%
Report Date
May 6, 2026
EPS Beat/Miss
-27.1%
Price Before
$7.26
Price After
$6.78
Q1 FY2026-1.45%
Report Date
Feb 25, 2026
EPS Beat/Miss
+34.3%
Price Before
$8.94
Price After
$8.81
Q4 FY2025-7.33%
Report Date
Nov 5, 2025
EPS Beat/Miss
+79.0%
Price Before
$9.00
Price After
$8.34
Q3 FY2025+3.18%
Report Date
Aug 7, 2025
EPS Beat/Miss
+20.0%
Price Before
$7.55
Price After
$7.79
Q2 FY2025+6.81%
Report Date
May 7, 2025
EPS Beat/Miss
+7.7%
Price Before
$13.95
Price After
$14.90
Q1 FY2025-0.27%
Report Date
Feb 25, 2025
EPS Beat/Miss
-70.0%
Price Before
$29.29
Price After
$29.21
Q4 FY2024-7.09%
Report Date
Nov 7, 2024
EPS Beat/Miss
+36.0%
Price Before
$54.73
Price After
$50.85
Q3 FY2024-2.37%
Report Date
Aug 5, 2024
EPS Beat/Miss
+27.3%
Price Before
$41.77
Price After
$40.78
Avg Beat Reaction-1.38%
Avg Miss Reaction-3.44%
Beat Rate6 / 8 quarters
Largest Move-7.33% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RXST ends December
RxSight, Inc. (RXST) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.38 — missing the analyst consensus of $-0.30 by -27.1%. The next RXST earnings date is expected around September 1, 2026.
Each quarter, investors track RXST earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RXST revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RXST's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RXST earnings · 5 questionsRxSight, Inc.'s next earnings report is expected around September 1, 2026. RXST typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RXST historically reports after market close (AMC).
RXST earnings datewhen is RXST earningsRXST next earnings datewhen does RXST report earningsRXST earnings calendar
▸ Source: FMP · RxSight, Inc. SEC filings · US GAAP · RxSight, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026